
CRISPR/Cas appears to be more effective at combating active HSV-1 infections than existing medications.
Video: https://youtu.be/lQaWh8VLkiU?is=TSQtipZzFd0B5s3C
What's next? CRISPR/Cas appears to be better able to combat active HSV-1 infections than existing drugs. However, follow-up research is urgently needed to apply this in a targeted manner.
Up until now, the targets of the adjective have been chosen at random. It is now important to determine exactly where the adjective can best be directed so that the cutting is as effective as possible.
It might then be possible to find and eliminate not only the active virus but also the dormant virus. Consequently, the virus will no longer be able to reactivate. It must also be determined how the CRISPR/Cas can be effectively delivered to those infected cells.